{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:52:22Z","timestamp":1784548342561,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["study number CTT116855"],"award-info":[{"award-number":["study number CTT116855"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple therapy with fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) versus FF\/VI and UMEC\/VI dual therapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>IMPACT was a 52-week, randomized, double-blind, multicenter Phase III study comparing the efficacy and safety of FF\/UMEC\/VI 100\/62.5\/25 mcg with FF\/VI 100\/25 mcg or UMEC\/VI 62.5\/25 mcg in patients \u226540\u2009years of age with symptomatic chronic obstructive pulmonary disease (COPD) and\u2009\u22651 moderate\/severe exacerbation in the previous year. The inclusion criteria for the study were intentionally designed to permit the enrollment of patients with significant concurrent CV disease\/risk. CV safety assessments included proportion of patients with and exposure-adjusted rates of on-treatment CV adverse events of special interest (CVAESI) and major adverse cardiac events (MACE), as well as time-to-first (TTF) CVAESI, and TTF CVAESI resulting in hospitalization\/prolonged hospitalization or death.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Baseline CV risk factors were similar across treatment groups. Overall, 68% of patients (<jats:italic>n<\/jats:italic>\u00a0=\u20097012) had \u22651 CV risk factor and 40% (<jats:italic>n<\/jats:italic>\u00a0=\u20094127) had \u22652. At baseline, 29% of patients reported a current\/past cardiac disorder and 58% reported a current\/past vascular disorder. The proportion of patients with on-treatment CVAESI was 11% for both FF\/UMEC\/VI and UMEC\/VI, and 10% for FF\/VI. There was no statistical difference for FF\/UMEC\/VI versus FF\/VI or UMEC\/VI in TTF CVAESI (hazard ratio [HR]: 0.98, 95% confidence interval [CI]: 0.85, 1.11; <jats:italic>p<\/jats:italic>\u00a0=\u20090.711 and HR: 0.92, 95% CI: 0.78, 1.08; <jats:italic>p<\/jats:italic>\u00a0=\u20090.317, respectively) nor TTF CVAESI leading to hospitalization\/prolonged hospitalization or death (HR: 1.19, 95% CI: 0.93, 1.51; <jats:italic>p<\/jats:italic>\u00a0=\u20090.167 and HR: 0.96, 95% CI: 0.72, 1.27; <jats:italic>p<\/jats:italic>\u00a0=\u20090.760, respectively). On-treatment MACE occurred in \u22643% of patients across treatment groups, with similar prevalence and rates between treatments.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In a symptomatic COPD population with a history of exacerbations and a high rate of CV disease\/risk, the proportion of patients with CVAESI and MACE was 10\u201311% and 1\u20133%, respectively, across treatment arms, and the risk of CVAESI was low and similar across treatment arms. There was no statistically significant increased CV risk associated with the use of FF\/UMEC\/VI versus FF\/VI or UMEC\/VI, and UMEC\/VI versus FF\/VI.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02164513\">NCT02164513<\/jats:ext-link> (GSK study number CTT116855).<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12931-020-01398-w","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T14:03:10Z","timestamp":1591365790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Single-inhaler triple therapy fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol and umeclidinium\/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Nicola C.","family":"Day","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanya","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Criner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Dransfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M. G.","family":"Halpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MeiLan K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Elaine","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morrys C.","family":"Kaisermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Kilbride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"1398_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report. 2019."},{"key":"1398_CR2","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.","journal-title":"PLoS Med"},{"key":"1398_CR3","unstructured":"World Health Organisation. The top 10 causes of death. Fact Sheet. 2018. Available from: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"1398_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1055\/s-0035-1556063","volume":"36","author":"N Putcha","year":"2015","unstructured":"Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med. 2015;36:575\u201391.","journal-title":"Semin Respir Crit Care Med"},{"key":"1398_CR5","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1136\/heartjnl-2016-310897","volume":"103","author":"RD Brook","year":"2017","unstructured":"Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, Magder S, Martinez FJ, Rajagopalan S, Vestbo J, et al. Cardiovascular outcomes with an inhaled beta2-agonist\/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017;103:1536\u201342.","journal-title":"Heart"},{"key":"1398_CR6","doi-asserted-by":"crossref","unstructured":"Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27.","DOI":"10.1183\/16000617.0057-2018"},{"key":"1398_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/14656566.2019.1570133","volume":"20","author":"P Rogliani","year":"2019","unstructured":"Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, Ora J. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2019;20:737\u201350.","journal-title":"Expert Opin Pharmacother"},{"key":"1398_CR8","doi-asserted-by":"publisher","first-page":"175346581775052","DOI":"10.1177\/1753465817750524","volume":"12","author":"AD Morgan","year":"2018","unstructured":"Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524.","journal-title":"Ther Adv Respir Dis"},{"key":"1398_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","volume":"198","author":"KM Kunisaki","year":"2018","unstructured":"Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Hartley BF, Martinez FJ, Newby DE, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198:51\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1398_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/thx.2010.157529","volume":"66","author":"JD Maclay","year":"2011","unstructured":"Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinnes C, Deans A, Newby DE, Mills NL, MacNee W. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011;66:769\u201374.","journal-title":"Thorax"},{"key":"1398_CR11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1513\/pats.200807-071TH","volume":"5","author":"W Macnee","year":"2008","unstructured":"Macnee W, Maclay J, McAllister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:824\u201333.","journal-title":"Proc Am Thorac Soc"},{"key":"1398_CR12","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1161\/01.CIR.0000056767.69054.B3","volume":"107","author":"DD Sin","year":"2003","unstructured":"Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514\u20139.","journal-title":"Circulation"},{"key":"1398_CR13","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2165\/00003495-200565120-00001","volume":"65","author":"M Cazzola","year":"2005","unstructured":"Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs. 2005;65:1595\u2013610.","journal-title":"Drugs"},{"key":"1398_CR14","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","volume":"125","author":"SR Salpeter","year":"2004","unstructured":"Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309\u201321.","journal-title":"Chest"},{"key":"1398_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/14740338.2018.1472232","volume":"17","author":"P Rogliani","year":"2018","unstructured":"Rogliani P, Ora J, Matera MG, Cazzola M, Calzetta L. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opin Drug Saf. 2018;17:589\u201396.","journal-title":"Expert Opin Drug Saf"},{"key":"1398_CR16","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/jama.300.12.1439","volume":"300","author":"S Singh","year":"2008","unstructured":"Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:1439\u201350.","journal-title":"JAMA"},{"key":"1398_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1465-9921-14-40","volume":"14","author":"RA Wise","year":"2013","unstructured":"Wise RA, Anzueto A, Calverley P, Dahl R, Dusser D, Pledger G, Koenen-Bergmann M, Joseph E, Cotton D, Disse B. The Tiotropium safety and performance in Respimat trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res. 2013;14:40.","journal-title":"Respir Res"},{"key":"1398_CR18","first-page":"239","volume":"10","author":"DM Halpin","year":"2015","unstructured":"Halpin DM, Dahl R, Hallmann C, Mueller A, Tashkin D. Tiotropium HandiHaler((R)) and Respimat((R)) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:239\u201359.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1398_CR19","doi-asserted-by":"crossref","unstructured":"Calzetta L, Cazzola M, Matera MG, Rogliani P. Adding a LAMA to ICS\/LABA therapy: a meta-analysis of triple combination therapy in COPD. Chest. 2019.","DOI":"10.1016\/j.chest.2018.12.016"},{"key":"1398_CR20","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.2147\/COPD.S146338","volume":"12","author":"P Rogliani","year":"2017","unstructured":"Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chron Obstruct Pulmon Dis. 2017;12:3469\u201385.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1398_CR21","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","volume":"387","author":"J Vestbo","year":"2016","unstructured":"Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE, Investigators S. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817\u201326.","journal-title":"Lancet"},{"key":"1398_CR22","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671\u201380.","journal-title":"N Engl J Med"},{"key":"1398_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1183\/13993003.02165-2015","volume":"48","author":"SJ Pascoe","year":"2016","unstructured":"Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, Dransfield MT, Pavord I, Barnes N. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48:320\u201330.","journal-title":"Eur Respir J"},{"key":"1398_CR24","unstructured":"Medical Dictionary for Regulatory Activities. 2019."},{"key":"1398_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.amepre.2014.03.014","volume":"47","author":"S Agarwal","year":"2014","unstructured":"Agarwal S, Rokadia H, Senn T, Menon V. Burden of cardiovascular disease in chronic obstructive pulmonary disease. Am J Prev Med. 2014;47:105\u201314.","journal-title":"Am J Prev Med"},{"key":"1398_CR26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1177\/1060028017719716","volume":"51","author":"JC Samp","year":"2017","unstructured":"Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA. Risk of cardiovascular and cerebrovascular events in COPD patients treated with long-acting beta2-agonist combined with a long-acting muscarinic or inhaled corticosteroid. Ann Pharmacother. 2017;51:945\u201353.","journal-title":"Ann Pharmacother"},{"key":"1398_CR27","doi-asserted-by":"crossref","unstructured":"Suissa S, Dell'Aniello S, Ernst P. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J. 2017;49.","DOI":"10.1183\/13993003.02245-2016"},{"key":"1398_CR28","unstructured":"European Network of Centres for Pharmcoepidemiology and Pharmacovigilance. Post-authorisation safety (PAS) observational cohort study to quantify the incidence and comparative safety of selected cardiovascular and cerebrovascular events in COPD patients using inhaled UMEC\/VI combination or inhaled UMEC versus Tiotropium (Study 201038; EU PAS 10316). Available from: http:\/\/www.encepp.eu\/encepp\/studySearch.htm."},{"key":"1398_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamainternmed.2017.7720","volume":"178","author":"MT Wang","year":"2018","unstructured":"Wang MT, Liou JT, Lin CW, Tsai CL, Wang YH, Hsu YJ, Lai JH. Association of Cardiovascular Risk with Inhaled Long-Acting Bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178:229\u201338.","journal-title":"JAMA Intern Med"},{"key":"1398_CR30","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076\u201384.","journal-title":"Lancet"},{"key":"1398_CR31","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","volume":"388","author":"D Singh","year":"2016","unstructured":"Singh D, Papi A, Corradi M, Pavlisova I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963\u201373.","journal-title":"Lancet"},{"key":"1398_CR32","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","volume":"389","author":"J Vestbo","year":"2017","unstructured":"Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389:1919\u201329.","journal-title":"Lancet"},{"key":"1398_CR33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/thoraxjnl-2011-200406","volume":"66","author":"LM Fabbri","year":"2011","unstructured":"Fabbri LM, Beghe B, Agusti A. Cardiovascular mechanisms of death in severe COPD exacerbation: time to think and act beyond guidelines. Thorax. 2011;66:745\u20137.","journal-title":"Thorax"},{"key":"1398_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00408-011-9301-8","volume":"189","author":"DM Halpin","year":"2011","unstructured":"Halpin DM, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT(R) trial. Lung. 2011;189:261\u20138.","journal-title":"Lung"},{"key":"1398_CR35","first-page":"A7344","volume":"199","author":"DA Lipson","year":"2019","unstructured":"Lipson DA, Criner G, Day N, Dransfield MT, Halpin DMG, Han M, Jones CE, Kilbride S, Lange P, Lomas DA, et al. Reduction in the risk of all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol compared to umeclidinium\/vilanterol in IMPACT including previously missing or censored vital status data. Am J Respir Crit Care Med. 2019;199:A7344.","journal-title":"Am J Respir Crit Care Med"},{"key":"1398_CR36","doi-asserted-by":"publisher","unstructured":"Lipson DA, Crim C, Criner G, Day N, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, et al. Reduction in all-cause mortality with Fluticason Furoate\/Umeclidinium\/Vilanterol in COPD patients. Am J Respir Crit Care Med. 2020. https:\/\/doi.org\/10.1164\/rccm.201911-2207OC. (epub ahead of print).","DOI":"10.1164\/rccm.201911-2207OC"},{"key":"1398_CR37","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","volume":"149","author":"L Calzetta","year":"2016","unstructured":"Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual Bronchodilation with LAMA\/LABA for the treatment of stable COPD. Chest. 2016;149:1181\u201396.","journal-title":"Chest"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01398-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-020-01398-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01398-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T23:15:32Z","timestamp":1622848532000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-01398-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-01398-w","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"26 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All study patients provided written informed consent. The study protocol, any amendments, the informed consent, and other information that required pre-approval were reviewed and approved by a national, regional, or investigational site ethics committee or institutional review board (IRB), in accordance with the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice and applicable country-specific requirements, including United States 21 Code of Federal Regulations 312.3(b) for constitution of independent ethics committees.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NC Day, S Kumar, CE Jones, M Kaisermann, S Kilbride, N Martin, and DA Lipson are GSK employees and hold stock\/shares in GSK. G Criner has received personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, CSA Medical, Eolo, GSK, HGE Technologies, Novartis, Nuvaira, Olympus, Pulmonx, Verona and NGM Bio. M Dransfield has received grant support from the Department of Defense and NIH; personal fees from AstraZeneca, Boehringer Ingelheim, PneumRx\/BTG, Genentech, Boston Scientific, Quark Pharmaceuticals and GSK; and contracted clinical trial support from Boehringer Ingelheim, Novartis, AstraZeneca, Yungjin, PneumRx\/BTG, Pulmonx, Boston Scientific and GSK. DMG Halpin has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, and Pfizer, and non-financial support from Boehringer Ingelheim and Novartis. MK Han has received personal fees from AstraZeneca, Boehringer Ingelheim, and GSK and research support from Novartis and Sunovion. P Lange has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, and GSK. DA Lomas has received personal fees from GSK. FJ Martinez has received personal fees and non-financial support from the American College of Chest Physicians, AstraZeneca, Boehringer Ingelheim, ConCert, Genentech, GSK, Inova Fairfax Health System, Miller Communications, National Society for Continuing Education, Novartis, Pearl Pharmaceuticals, PeerView Communications, Prime Communications, Puerto Rico Respiratory Society, Chiesi, Sunovion, Theravance, Potomac, University of Alabama Birmingham, Physicians Education Resource, Canadian Respiratory Network, Teva and Dartmouth; non-financial support from ProterrixBio, Gilead, Nitto and Zambon; and personal fees from Columbia University, Integritas, MD magazine, Methodist Hospital Brooklyn, New York University, UpToDate, WebMD\/MedScape, Western Connecticut Health Network, Patara\/Respivant, PlatformIQ, American Thoracic Society, Rockpointe, Rare Disease Healthcare Communications and France Foundation; grant support from NIH; and is a member of steering committees for Afferent\/Merck, Biogen, Veracyte, Prometic, Bayer, Bridge Biotherapeutics and ProMedior. D Singh has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, Glenmark, GSK, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Theravance, and Verona. R Wise has received personal fees from AstraZeneca\/MedImmune, Boehringer Ingelheim, Contrafect, Pulmonx, Roche, Spiration, Sunovion, Merck, Circassia, GSK, Pneuma, Verona, Bonti, Denali, Aradigm, Mylan\/Theravance, Propeller Health and AbbVie; and grant support from AstraZeneca\/MedImmune, Boehringer Ingelheim, Pearl Therapeutics, GSK and Sanofi-Aventis.ELLIPTA is owned by or licensed to the GSK Group of Companies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}